InvestLog
NEUP Neuphoria Therapeutics Inc. logo

NEUP Neuphoria Therapeutics Inc.

Healthcare
$5.48+7.03%ClosedMarket Cap: $29.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.01

P/S

-2.83

EV/EBITDA

-0.45

DCF Value

$50.44

FCF Yield

200.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

101.6%

Operating Margin

255.7%

Net Margin

263.1%

ROE

-109.7%

ROA

-79.2%

ROIC

-79.4%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 null$0.00$-505.1K$—
Q2 null$0.00$2.8M$—
Q1 null$0.00$-15.0M$—
Q4 null$-10.5M$-14.9M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$7.00

Target (Median)

$7.00

Target Range

$7.00 - $7.00

1 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Neutral
2026-05-15
HC Wainwright & Co.Buy
2025-12-05
Maxim GroupBuy
2025-09-11
HC Wainwright & Co.Buy
2025-08-26

Trading Activity

Insider Trades

View All
Wilson David Iandirector
SellWed Jan 21
Ryan Janedirector
SellWed Jan 21
Fisher Alandirector
SellWed Jan 21
Davies Peter Miles Winstondirector
SellWed Jan 21
Lynx1 Capital Management LP10 percent owner
BuyThu Oct 23

Company Info

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

US

Exchange

—

Beta

0.72

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Peers

ALZN logoALZNAPRE logoAPREBCDA logoBCDABMRA logoBMRACHEK logoCHEKIINN logoIINNLFWD logoLFWDLUCY logoLUCYPFSA logoPFSAPTHL logoPTHL